Clinical Trial Update: Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on extended peri-operative tinzaparin to improve disease-free survival in resectable colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Colon

Drugs mentioned

• tinzaparin (tinzaparin)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Adenocarcinoma of the Colon | Phase 3 | Status: COMPLETED